Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Consun Pharmaceutical GroupCPHGF +9.09%71 Earnings Yield (Joel Greenblatt) % is 14.18% as of Dec. 2025, which is 27% below its 10-year median of 19.55. GuruFocus rates CPHGF with a GF Score™ of 71/100 and a GF Value™ of $1.12 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 1,009 Drug Manufacturers companies, Consun Pharmaceutical Group ranks better than 92.27% on this metric.
Consun Pharmaceutical Group's Enterprise Value for the quarter that ended in Dec. 2025 was $459.9 Mil.
Consun Pharmaceutical Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $169.0 Mil. Consun Pharmaceutical Group's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2025 was 14.18%.
The historical rank and industry rank for Consun Pharmaceutical Group's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
CPHGF'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: 5.26 Med: 19.55 Max: 149.04
Current: 17.61
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Consun Pharmaceutical Group was 149.04%. The lowest was 5.26%. And the median was 19.55%.
CPHGF's Earnings Yield (Joel Greenblatt) % is ranked better than 92.27% of 1009
companies
in the Drug Manufacturers industry
Industry Median: 3.02
vs CPHGF: 17.61
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Consun Pharmaceutical Group's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2025 was 17.27%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Consun Pharmaceutical Group (OTCPK:CPHGF) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Consun Pharmaceutical Group Earnings Yield (Joel Greenblatt) % Related Terms
Consun Pharmaceutical Group Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Consun Pharmaceutical Group's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Consun Pharmaceutical Group Earnings Yield (Joel Greenblatt) % Chart
CPHGF vs ZTS: Earnings Yield (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Consun Pharmaceutical Group's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Consun Pharmaceutical Group Earnings Yield (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Consun Pharmaceutical Group's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Consun Pharmaceutical Group's Earnings Yield (Joel Greenblatt) % falls into.
Consun Pharmaceutical Group Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Consun Pharmaceutical Groups Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
For company reported semi-annually or annually, GuruFocus only calculate annual data for Earnings Yield (Joel Greenblatt) and apply the annual figure to corresponding quarter.
What does a Earnings Yield (Joel Greenblatt) % of 14.18% mean?
Consun Pharmaceutical Group (CPHGF) has a Earnings Yield (Joel Greenblatt) % of 14.18% as of Dec. 2025. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Consun Pharmaceutical Group and its competitors. This is 27% below median its historical median of 19.55. Over the past decade, Consun Pharmaceutical Group's Earnings Yield (Joel Greenblatt) % has ranged from 5.26 to 149.04. According to the industry distribution chart, Consun Pharmaceutical Group ranks #78 out of 1009 companies in the Drug Manufacturers industry, placing it in the top 7.7%.
Is Consun Pharmaceutical Group's Earnings Yield (Joel Greenblatt) % too high?
Consun Pharmaceutical Group's current Earnings Yield (Joel Greenblatt) % of 14.18% is 27% below median its 10-year median of 19.55. Over the past 10 years, this metric has ranged from a low of 5.26 to a high of 149.04. The Drug Manufacturers industry median Earnings Yield (Joel Greenblatt) % is 3.02. Consun Pharmaceutical Group's value of 14.18% is 369.5% above this industry median. Based on the distribution chart, Consun Pharmaceutical Group ranks #78 out of 1009 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Consun Pharmaceutical Group has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Consun Pharmaceutical Group's Earnings Yield (Joel Greenblatt) % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Consun Pharmaceutical Group ranks #78 out of 1009 companies for Earnings Yield (Joel Greenblatt) %. This places Consun Pharmaceutical Group in the top 8% of its industry — outperforming the majority of peers. The industry median Earnings Yield (Joel Greenblatt) % is 3.02. Consun Pharmaceutical Group's value of 14.18% is 369.5% above this benchmark. Historically, Consun Pharmaceutical Group's own Earnings Yield (Joel Greenblatt) % has ranged from 5.26 to 149.04 over the past decade. While the company's 10-year median is 19.55 vs. the industry median of 3.02, Consun Pharmaceutical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Drug Manufacturers company?
The median Earnings Yield (Joel Greenblatt) % among Drug Manufacturers companies is 3.02, based on 1,009 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Consun Pharmaceutical Group's current Earnings Yield (Joel Greenblatt) % of 14.18% is 369.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Consun Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median Earnings Yield (Joel Greenblatt) % is 3.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Consun Pharmaceutical Group's current Earnings Yield (Joel Greenblatt) % is 14.18%, which is 27% below median its own 10-year median of 19.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Consun Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, Consun Pharmaceutical Group (CPHGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.12, compared to a current price of $1.80 — trading 60.7% above its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 14.18%, which is 27% below median its 10-year median of 19.55 and 369.5% above the Drug Manufacturers industry median of 3.02. Consun Pharmaceutical Group's overall GF Score™ is 71/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Consun Pharmaceutical Group (CPHGF), the current Earnings Yield (Joel Greenblatt) % is 14.18% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Consun Pharmaceutical Group (CPHGF) Overvalued in 2026?
Based on GuruFocus' analysis, Consun Pharmaceutical Group stock appears to be overvalued.
The current stock price of $1.80 is trading 60.7% above its estimated GF Value™ of $1.12.
GuruFocus considers Consun Pharmaceutical Group to be Significantly Overvalued.
Key valuation signals for CPHGF:
Earnings Yield (Joel Greenblatt) %: 14.18% (27% below median its 10-year median of 19.55)
GF Value™: $1.12 vs. price of $1.80 (60.7% above fair value)
Industry Position: 369.5% above the Drug Manufacturers median (#78 of 1009)
No single metric tells the full story. See the CPHGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Consun Pharmaceutical Group Ltd is a biotechnology company with a modern pharmaceutical enterprise that integrates R&D, production, and marketing. The company has two reportable segments: the Consun pharmaceutical segment, which is the key revenue driver, and makes and sells modern Chinese medicines and medical contrast medium, and the Yulin pharmaceutical segment, which manufactures and sells traditional Chinese medicines. Company derives revenue from kidney medicines, contrast mediums, orthopedics medicines, dermatologic medicines, hepatobiliary medicines, medicines for women and children, and others.
71GF Score
Get the complete analysis for CPHGF
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CPHGF has been successfully added to your 
